Live tape
Top 8, mentions 7d11,038TSLA2,547 mentions▲ +0.06SPCX2,146 mentions▲ +0.08GOOGL1,387 mentions▲ +0.04CRWV1,208 mentions▲ +0.04NVDA1,091 mentions▲ +0.07QQQ1,042 mentions▲ +0.05META836 mentions▲ +0.05NBIS781 mentions▲ +0.07

Equity · Healthcare

SUPN

NASDAQ

Supernus Pharmaceuticals (SUPN)

$43.77 −0.52% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 1, 2026
Price · Chart
25 sessions
$50 $42 29 Jul 1 Sep

The line runs $46.59 on 29 July through $43.77 on 1 September, on a scale from $42 to $50. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 25 sessions, 29 Jul – 1 Sep 2026
Market cap $2.5B
52-week range $43.24 – $57
Avg volume 164.8K

as of Sep 1, 2026

Supernus Pharmaceuticals (SUPN) insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 12 Aug 2026

In the 90 days to 21 Oct 2026, no Supernus Pharmaceuticals insider bought or sold shares on the open market; all 10 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Open-market buys 0
Open-market sells 0
Non-trade filings 10

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
12 Aug 2026 Bhatt Padmanabh P. Sr. VP of IP, CSO Option exercise 2,500
12 Aug 2026 Bhatt Padmanabh P. Sr. VP of IP, CSO Tax withheld 1,158 $54K
12 Aug 2026 DEC TIMOTHY C Senior Vice-President & CFO Option exercise 1,250
12 Aug 2026 DEC TIMOTHY C Senior Vice-President & CFO Tax withheld 604 $28K
12 Aug 2026 Khattar Jack A. President, CEO Option exercise 29,849
12 Aug 2026 Khattar Jack A. President, CEO Tax withheld 12,642 $589K
12 Aug 2026 Mottola Frank SVP, Chief Tech. Ops. Officer Option exercise 1,650
12 Aug 2026 Mottola Frank SVP, Chief Tech. Ops. Officer Tax withheld 797 $37K
12 Aug 2026 Rubin Jonathan SVP, Chief Medical Officer Option exercise 750
12 Aug 2026 Rubin Jonathan SVP, Chief Medical Officer Tax withheld 363 $17K

Supernus Pharmaceuticals (SUPN) reported financials

SEC EDGAR XBRL SEC EDGAR

Supernus Pharmaceuticals reported revenue of $719.0M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$38.6M.

Figure Reported Period
Revenue $719.0M 31 Dec 2025 fiscal year
Net income −$38.6M 31 Dec 2025 fiscal year
Diluted EPS −$0.68 31 Dec 2025 fiscal year
Total assets $1.4B 30 Jun 2026 at period end
Total equity $1.0B 30 Jun 2026 at period end

Supernus Pharmaceuticals (SUPN) earnings

SEC EDGAR

Supernus Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.01; the next report is scheduled for 29 Oct 2026 (SEC filings).

Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$1.01 —
31 Mar 2026 Q1 2026 −$0.04 —
31 Dec 2025 FY 2025 −$0.68 —
30 Sep 2025 Q3 2025 −$0.80 —
30 Jun 2025 Q2 2025 $0.40 —
31 Mar 2025 Q1 2025 −$0.21 —
31 Dec 2024 FY 2024 $1.32 —
30 Sep 2024 Q3 2024 $0.69 —

Next report 29 Oct 2026

Reported figures & scheduled dates · SEC EDGAR filings

Supernus Pharmaceuticals (SUPN) institutional holders (13F)

SEC Form 13F SEC EDGAR

9 of the 45 institutional funds we track reported a Supernus Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined $419.2M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Millennium Management Held (±25%) +16.2% shares 3,853,212 $179.2M
Renaissance Technologies Held (±25%) −13.3% shares 1,478,180 $68.8M
Citadel Advisors Held (±25%) −8.0% shares 1,373,982 $63.9M
Two Sigma Investments Added +336.7% shares 1,184,378 $55.1M
D. E. Shaw & Co. Held (±25%) +23.3% shares 767,668 $35.7M
Man Group Added +108.6% shares 156,422 $7.3M
AQR Capital Management Held (±25%) −9.7% shares 88,756 $4.1M
Balyasny Asset Management Added +1,172.7% shares 85,756 $4.0M
Tudor Investment Corp New position 24,746 $1.2M
Point72 Asset Management Exited

Supernus Pharmaceuticals (SUPN) fails-to-deliver

SEC CNS data SEC

On 25 Sep 2026, 1 shares of Supernus Pharmaceuticals failed to deliver (about $43).

Settlement date Shares failed Notional % of shares out
25 Sep 2026 1 $43 <0.001%
23 Sep 2026 41 $2K <0.001%
22 Sep 2026 49 $2K <0.001%
08 Sep 2026 9,121 $397K 0.016%

Congressional trades in Supernus Pharmaceuticals (SUPN)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Supernus Pharmaceuticals is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 09 Oct 2025.

Date Member Type Amount
09 Oct 2025 filed 18 Nov 2025 Gilbert Ray Cisneros, Jr. house · Democrat–CA Sale $1K–$15K
24 Mar 2025 filed 07 Apr 2025 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
23 Dec 2022 filed 13 Jan 2023 Josh Gottheimer house · Democrat–NJ Sale $1K–$15K
01 Jun 2020 filed 16 Jun 2020 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
28 May 2020 filed 10 Jun 2020 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K

Supernus Pharmaceuticals (SUPN): frequently asked questions

From live data

Have Supernus Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, no Supernus Pharmaceuticals insider bought or sold shares on the open market; all 10 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

How many institutions hold Supernus Pharmaceuticals?

9 of the 45 institutional funds we track reported a Supernus Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Supernus Pharmaceuticals had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Supernus Pharmaceuticals is dated 25 Sep 2026, when 1 shares failed to deliver.

When did Supernus Pharmaceuticals last report earnings?

Supernus Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.01; the next report is scheduled for 29 Oct 2026 (SEC filings).

What exchange is Supernus Pharmaceuticals listed on?

Supernus Pharmaceuticals trades on NASDAQ under the ticker SUPN.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings